Skip to main content
Fig. 7 | Stem Cell Research & Therapy

Fig. 7

From: Intramyocardial injected human umbilical cord-derived mesenchymal stem cells (HucMSCs) contribute to the recovery of cardiac function and the migration of CD4+ T cells into the infarcted heart via CCL5/CCR5 signaling

Fig. 7

The CCR5 antagonist inhibited the cardioprotective effect of HucMSCs administration post MI injury. A The flow diagram of the experiment design. The three groups: MI-N.S, MI-HucMSC and MI-HucMSC-CCR5 antagonist. After MI injury was established, mice were immediately injected N.S or HucMSCs by three points into the peri-infarcted heart zone. Then, the MI-HucMSC-CCR5 antagonist group was intraperitoneally injected 20 mg/kg/d CCR5 antagonist. B Representative echocardiographic images (M-mode) in three groups on day 7 following MI surgery. C Statistical results of cardiac function on day 7 among MI-N.S (n = 6), MI-HucMSC (n = 6) and MI-HucMSC-CCR5 antagonist (n = 6) groups. *p < 0.05 versus MI-N.S group; #p < 0.05 versus MI-HucMSC group

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512